University of Nebraska Medical Center

DigitalCommons@UNMC
Posters: 2021 Summer Undergraduate
Research Program

Summer Undergraduate Research Program

Summer 8-12-2021

The Role of PAF1/PD2 in Inducing Drug Resistance In Pancreatic
Cancer Cells
Aditi Jain
University of Nebraska Medical Center

Sanchita Rauth
University of Nebraska Medical Center

Surinder K. Batra
University of Nebraska Medical Center

Moorthy P. Ponnusamy
University of Nebraska Medical Center

Follow this and additional works at: https://digitalcommons.unmc.edu/surp2021

Recommended Citation
Jain, Aditi; Rauth, Sanchita; Batra, Surinder K.; and Ponnusamy, Moorthy P., "The Role of PAF1/PD2 in
Inducing Drug Resistance In Pancreatic Cancer Cells" (2021). Posters: 2021 Summer Undergraduate
Research Program. 16.
https://digitalcommons.unmc.edu/surp2021/16

This Poster is brought to you for free and open access by the Summer Undergraduate Research Program at
DigitalCommons@UNMC. It has been accepted for inclusion in Posters: 2021 Summer Undergraduate Research
Program by an authorized administrator of DigitalCommons@UNMC. For more information, please contact
digitalcommons@unmc.edu.

The Role of PAF1/PD2 in Inducing Drug Resistance
in Pancreatic Cancer Cells
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Dr. Moorthy P. Ponnusamy1, PhD
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RESULTS
• Pancreatic cancer (PC), a highly aggressive human cancer, is the third
leading cause of death due to cancer, with a five-year survival rate1.
• Cancer stem cells (CSCs) are a small and distinct population of cancer
cells that mediate tumorigenesis, metastasis and resistance to standard
treatments1.
• Specifically identifying and targeting CSC maintenance genes can improve
the efficiency of treatment modalities5.
• PAF1 (RNA Polymerase II-Associated Factor 1), also known as PD2
(Pancreatic Differentiation 2), is the core subunit of the human PAF1
complex (PAF1C). It maintains pluripotency of stem cells and is a marker
of pancreatic CSCs2 3.
• PAF1/PD2 is upregulated in poorly differentiated pancreatic cancer cells2.
• Gemcitabine (Gem) is a novel deoxycytidine analogue developed as an
anticancer therapy4. It is widely used as a chemotherapeutic agent and is
presently the most effective agent against pancreatic cancer5.
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Fig.1: A) Western blot depicting the Gemcitabine treated population exhibiting a higher expression of CD44 and PAF1/PD2 in comparison to the control
population. B) Western blot depicting SP cells exhibiting a higher expression of PAF1, MDR1 and CD44 in comparison to NSP cells. C) Addition of
Gemcitabine caused a significant increase in the expression of CSC markers (PAF1, ABCB1, CXCR4, CD133, ALDH1, and ZO-1). D) Confocal
microscopy analysis of a Gemcitabine resistant population which shows a higher expression compared to the control population in MIAPaCa2 and
SW1990 PC cell lines.

Loss of PAF1/PD2 influences maintenance of PC cells and
sensitizes the cells to Gemcitabine
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EXPERIMENTAL DESIGN AND METHODS
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Experiments performed:
QRT-PCR
SP Analysis
Sphere Assay
Colony formation Assay
Western Blot
Confocal Microscopy Analysis
MTT Assay
Cell Proliferation
Apoptotic Assay
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HYPOTHESIS
PAF1/PD2 plays a role in the maintenance of Pancreatic cancer stem cells
and contributes to Gemcitabine resistance.
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BACKGROUND

Fig.2: A) MTT Assay depicting the knockdown of PAF1/PD2 leading to a decrease in the MIAPaCa2 PC cell line as compared to the control and Gemcitabine resistant
populations. B) In vitro colony formation tumorigenesis assay performed using 1.0 x 103 PC cells which were fixed and stained after 14 days in culture. C) Cell
proliferation analysis displaying a decrease in cells in PAF1/PD2 knockdown compared to the control group. D) Apoptotic Assay depicting higher cell death with
PAF1/PD2 knockdown.

Impact of PAF1/PD2 on Gemcitabine Resistance
and CSC marker expression
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Fig. 4: A) Data obtained from cBioPortal demonstrating that 5% of PC patients out of 100 were shown to have higher levels of PAF1. B) Data obtained
from Gepia demonstrating that tumor patients had higher levels of PAF1/PD2 in comparison to normal patients. C) The survival rate comparison
between the altered group (samples with at least one alteration in PAF1 in PC patients) and unaltered group (samples without any alterations in PAF1 in
PC patients) over a period of 178 months. D) Composite score comparison of PAF1/PD2 between normal/benign tumor vs. malignant tumor depicting
higher levels of PAF1/PD2 in a malignant tumor.

CONCLUSION
• PAF1/PD2 are over expressed in Pancreatic Tumor cells, specifically in
cancer stem cells (CSCs).
• Increased expression of PAF1/PD2 is associated with gemcitabine
resistance in pancreatic cancer cells.
• The knockdown of PAF1/PD2 leads to a significant reduction in expression
of CSC markers and pancreatic tumorigenesis.
• Human pancreatic tumor samples showed increased expression of
PAF1/PD2. Additionally, altered expression of PAF1/PD2 has prognostic
relevance to pancreatic cancer patient survival.

FUTURE DIRECTIONS
• Identify the specific inhibitor for PAF1/PD2 using an In-silico analysis
• Test the efficacy of PAF1/PD2 inhibitor in cancer stem cell and drug resistant models
• Investigate the therapeutic efficacy of PAF1/PD2 inhibitor along with gemcitabine using
preclinical models
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